Daraxonrasib, which is awaiting FDA approval, could double the life expectancy of people with advanced disease.

Average wait times from diagnosis to first treatment grew by more than 10 days across all six cancer types studied.

The treatment eliminated a boy's tumors with a single infusion.

Enhertu (trastuzumab deruxtecan) kept cancer from growing longer than the current standard first treatment did in patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous ...

A cancer diagnosis can leave you speechless, even if you’re a card-carrying extrovert. It’s one word no one wants to hear, but unfortunately, more than 1 million new cases of cancer are diagnosed each ...

A new pancreatic cancer drug nearly doubled survival in a major trial, giving patients and doctors new hope against a deadly ...

Dr. Nitin Verma, an oncologist at Kaiser Permanente, said there's no scientific evidence showing that ivermectin is safe or ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A major medical breakthrough might have been achieved while researching ...

AstraZeneca ditches lung cancer treatment trial - The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

As the sun continues to beat down across Texoma, the medical experts of Texas Oncology are warning the community to be aware of skin cancer risks.

Two new scalp cooling machines are donated to East Surrey and Crawley Hospitals.